129 related articles for article (PubMed ID: 19356091)
1. Troglitazone thiol adduct formation in human liver microsomes: enzyme kinetics and reaction phenotyping.
Gan J; Qu Q; He B; Shyu WC; Rodrigues AD; He K
Drug Metab Lett; 2008 Aug; 2(3):184-9. PubMed ID: 19356091
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction.
He K; Woolf TF; Kindt EK; Fielder AE; Talaat RE
Biochem Pharmacol; 2001 Jul; 62(2):191-8. PubMed ID: 11389877
[TBL] [Abstract][Full Text] [Related]
3. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes.
Yamazaki H; Shibata A; Suzuki M; Nakajima M; Shimada N; Guengerich FP; Yokoi T
Drug Metab Dispos; 1999 Nov; 27(11):1260-6. PubMed ID: 10534310
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.
Tettey JN; Maggs JL; Rapeport WG; Pirmohamed M; Park BK
Chem Res Toxicol; 2001 Aug; 14(8):965-74. PubMed ID: 11511170
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.
He K; Talaat RE; Pool WF; Reily MD; Reed JE; Bridges AJ; Woolf TF
Drug Metab Dispos; 2004 Jun; 32(6):639-46. PubMed ID: 15155556
[TBL] [Abstract][Full Text] [Related]
7. Identification of glutathione conjugates of troglitazone in human hepatocytes.
Prabhu S; Fackett A; Lloyd S; McClellan HA; Terrell CM; Silber PM; Li AP
Chem Biol Interact; 2002 Nov; 142(1-2):83-97. PubMed ID: 12399157
[TBL] [Abstract][Full Text] [Related]
8. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
Masubuchi Y
Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
11. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of an oxygen from water into troglitazone quinone by cytochrome P450 and myeloperoxidase.
He K; Talaat RE; Woolf TF
Drug Metab Dispos; 2004 Apr; 32(4):442-6. PubMed ID: 15039298
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
14. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.
Projean D; Morin PE; Tu TM; Ducharme J
Xenobiotica; 2003 Aug; 33(8):841-54. PubMed ID: 12936704
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Yamazaki H; Suzuki M; Tane K; Shimada N; Nakajima M; Yokoi T
Xenobiotica; 2000 Jan; 30(1):61-70. PubMed ID: 10659951
[TBL] [Abstract][Full Text] [Related]
16. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of troglitazone in hepatocytes isolated from experimentally induced diabetic rats.
Meechan AJ; Henderson C; Bates CD; Grant MH; Tettey JN
J Pharm Pharmacol; 2006 Oct; 58(10):1359-65. PubMed ID: 17034659
[TBL] [Abstract][Full Text] [Related]
18. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes.
Sahi J; Hamilton G; Sinz M; Barros S; Huang SM; Lesko LJ; LeCluyse EL
Xenobiotica; 2000 Mar; 30(3):273-84. PubMed ID: 10752642
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
Säll C; Houston JB; Galetin A
Drug Metab Dispos; 2012 Jul; 40(7):1279-89. PubMed ID: 22451699
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
